Management and Board of Directors
Dr. Glenn Larsen
and CEO of Aquinnah
Dr. Larsen brings a unique skill set to his role as CEO—he is both a highly experienced scientist and a skillful businessman with a Ph.D. in biochemistry and a PMD from Harvard.
He has been a drug hunter all his life and has a deep understanding of how to create successful drugs. Dr. Larsen's track record speaks for itself: he has led teams to advance 15 new drug candidates to clinical development and 5 drugs to commercialization with sales over $10B.
During a notable career at major pharmaceutical companies, Dr. Larsen was involved in all facets of drug research and development, including leading drug discovery teams, and advancing drug development programs through the preclinical, clinical, regulatory and commercialization stages.
Mr. Carpenter is a pioneer in the biotechnology and healthcare industries. He founded and was CEO of a number of successful biotech companies he took public, including Integrated Genetics and GelTex Pharmaceuticals, both of which were acquired by Genzyme. Mr. Carpenter served on the Board of Genzyme from 1994 to 2011, most recently as Lead Director.
He also founded Boston Medical Investors in 1994 and currently serves as a Director of Good Start Genetics, Olaris Therapeutics, Immuneering Inc, Hydra Biosciences, and Lysosomal Therapeutics, Inc.
Mr. Carpenter is a graduate of West Point, Stanford University and holds an MBA from Harvard Business School.
Dr. Ben Wolozin
Co-Founder and the Chief Scientific Officer
Professor of Pharmacology and Neurology, Boston University School of Medicine
Dr. Wolozin holds an MD and Ph.D. degree and has extensive research experience in this field. He is a distinguished scientist who identified one of the first molecular markers for the tangle pathology that accumulates in neurons in Alzheimer’s disease. He was also the first to identify the link between the use of statins (a cholesterol lowering drug) and reduced rates of Alzheimer’s disease. More recently, he discovered the role of persistent stress granules in ALS and Alzheimer’s disease.
He has won multiple awards for his research, including the prestigious Zenith Fellows Award and the A. E. Bennett award from the Society for Neuroscience.
Travis T. Wager, Ph.D.
Vice President, Research
Dr. Wager is a leader in in the pharmaceutical industry. In his almost 20 years of leadership experience driving Neuroscience research and drug discovery programs at Pfizer, Dr. Wager advanced eight small molecule drug candidates to clinical development, including the first kinase inhibitor for a CNS indication. Dr. Wager became internationally recognized as an expert in the field of brain-penetrant small molecule design. His seminal contributions to
the understanding of CNS drug physicochemical properties and the development of the CNS MPO desirability tool has enabled both small and large neuroscience pharmaceutical groups to accelerate CNS drug discovery. In addition, he has published extensively and authored almost 40 scientific papers, including two most cited papers, and is an inventor on over 30 patents, and serves on the Scientific Advisory Board of ACS Chemical Neuroscience.